April 22nd 2024
An additional seven lots of Treprostinil are affected on top of last month’s recall of one lot.
April 2nd 2024
March 29th 2024
FDA Requires New Labeling for Antidepressants
October 4th 2021The labeling for selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake Inhibitors (SSNRIs) now must include information about sexual side effects in the warning and precautions and patient counseling sections.
Read More
FDA’s New Warning Includes Xeljanz and other JAK Inhibitors
September 3rd 2021The FDA’s review of the JAK inhibitor class concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with these arthritis and ulcerative colitis medicines.
Read More
Hospital Pharmacists Concerned About Actemra Shortage
September 2nd 2021Pharmacists are referring patients elsewhere or are shifting patients who were using the IV form to the subcutaneous injection. The NIH has also recommended using Kevzara as an alternative where there are shortages of Actemra.
Read More